NCT05496595View on ClinicalTrials.gov

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

February 5, 2024

Study Completion Date

February 5, 2024

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

DCBY02

A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.

Trial Locations (3)

80045

University of Colorado, Aurora

85258

Honor Health, Scottsdale

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

DynamiCure Biotechnology

INDUSTRY